734 S. Hayashi et al. of adrenalectomy, radical nephrectomy and radical prostatec- tomy. Aktuelle Urol 2010;41(Suppl 1):S15–9. 15. Schmid HP, McNeal JE, Stamey TA. Observations on the doub- ling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of in- creasing cancer volume. Cancer 1993;71:2031–40. 16. Brooks JP, Albert PS, O’Connell J et al. Lymphovascular in- vasion in prostate cancer: prognostic significance in patients treated with radiotherapy after radical prostatectomy. Cancer 2006;106:1521–6. 17. Salomao DR, Graham SD, Bostwick DG. Microvascular invasion in prostate cancer correlates with pathologic stage. Arch Pathol Lab Med 1995;119:1050–4. 18. Bahnson RR, Dresner SM, Gooding W et al. Incidence and prognostic significance of lymphatic and vascular invasion in radical prostatectomy specimens. Prostate 1989; 15:149–55. 19. Stephenson AJ, Kattan MW, Eastham JA et al. Defining bio- chemical recurrence of prostate cancer after radical prostatec- tomy: a proposal for a standardized definition. J Clin Oncol 2006;24:3973–8. 20. Geinitz H, Riegel MG, Thamm R et al. Outcome after con- formal salvage radiotherapy in patients with rising prostate- specific antigen levels after radical prostatectomy. Int J Radiat Oncol Biol Phys 2012;82:1930–7.